| 101 |
11440283 | Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. | 2001 Jun |
2 |
| 102 |
11498717 | L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. | 2001 Aug |
2 |
| 103 |
11586115 | Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. | 2001 Sep-Oct |
1 |
| 104 |
10703007 | [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. | 2000 Feb |
1 |
| 105 |
10733264 | Comparative tolerability of the newer generation antiparkinsonian agents. | 2000 Jan |
1 |
| 106 |
10766888 | The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. | 2000 May |
4 |
| 107 |
10858804 | The role of entacapone in the management of Parkinson's disease. | 2000 Apr |
1 |
| 108 |
10882160 | Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. | 2000 Jun |
2 |
| 109 |
10900396 | Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study. | 2000 Oct 1 |
2 |
| 110 |
10981253 | Entacapone. | 2000 Sep |
2 |
| 111 |
11038168 | The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. | 2000 Nov |
1 |
| 112 |
11147507 | Issues important for rational COMT inhibition. | 2000 |
1 |
| 113 |
11147508 | Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. | 2000 |
1 |
| 114 |
11147509 | Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials. | 2000 |
2 |
| 115 |
11147510 | COMT inhibitors and liver toxicity. | 2000 |
1 |
| 116 |
11147511 | Practical issues with COMT inhibitors in Parkinson's disease. | 2000 |
2 |
| 117 |
11147512 | The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. | 2000 |
1 |
| 118 |
10027643 | Separation of the glucuronides of entacapone and its (Z)-isomer in urine by micellar electrokinetic capillary chromatography. | 1999 Jan 8 |
2 |
| 119 |
10220913 | Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine. | 1999 Mar 19 |
2 |
| 120 |
10229966 | [Entacapone++ : a new catechol-O-methyltransferase inhibitor which improves the response to levodopa in patients with Parkinson disease and fluctuating motor function]. | 1999 Mar 1-15 |
1 |
| 121 |
10363328 | [Entacapone: is it useful as complimentary treatment with levodopa?]. | 1999 Apr 16-30 |
4 |
| 122 |
10410761 | COMT inhibition with entacapone in the treatment of Parkinson's disease. | 1999 |
1 |
| 123 |
10439935 | Entacapone. A review of its use in Parkinson's disease. | 1999 Jul |
2 |
| 124 |
10451758 | COMT inhibitors in Parkinson's disease. | 1999 Aug |
1 |
| 125 |
10492060 | Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. | 1999 Aug |
3 |
| 126 |
10555945 | Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications. | 1999 Nov |
1 |
| 127 |
10570622 | [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease]. | 1999 Aug-Sep |
4 |
| 128 |
11503812 | Entacapone: new preparation. Comparative data are lacking. | 1999 Dec |
1 |
| 129 |
12973467 | Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies. | 1999 Sep |
1 |
| 130 |
15992091 | Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson's disease: review and current status. | 1999 Apr |
3 |
| 131 |
9591516 | COMT inhibition: a new treatment strategy for Parkinson's disease. | 1998 May |
2 |
| 132 |
9591519 | Influence of COMT inhibition on levodopa pharmacology and therapy. | 1998 May |
1 |
| 133 |
9633684 | Extending levodopa action: COMT inhibition. | 1998 Jun |
3 |
| 134 |
9681662 | Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. | 1998 May |
4 |
| 135 |
9808337 | COMT inhibition in the treatment of Parkinson's disease. | 1998 Nov |
3 |
| 136 |
9818851 | Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. | 1998 Nov |
2 |
| 137 |
9232524 | Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. | 1997 Jul |
3 |
| 138 |
9251066 | Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. | 1997 Jul |
1 |
| 139 |
9337447 | New pharmacotherapy for Parkinson's disease. | 1997 Oct |
2 |
| 140 |
9372556 | Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. | 1997 Dec |
1 |
| 141 |
9392574 | Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. | 1997 Nov |
1 |
| 142 |
8558148 | Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. | 1996 Jan |
1 |
| 143 |
8612391 | Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. | 1996 Apr |
2 |
| 144 |
8726541 | Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. | 1996 Jun |
1 |
| 145 |
8738181 | Validation of assay of catechol-O-methyltransferase activity in human erythrocytes. | 1996 Mar |
2 |
| 146 |
8784230 | Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. | 1996 Sep |
2 |
| 147 |
8836934 | COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. | 1996 |
3 |
| 148 |
9010698 | Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. | 1996 |
2 |
| 149 |
7648772 | The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. | 1995 Aug |
3 |
| 150 |
8665534 | Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. | 1995 Feb |
4 |